Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC01 in chronic advanced HFrEF
2025-524469-25-00Phase 2Authorised
- Sponsor
- AnaCardio
- Start
- Oct 2026
- Modality
- Small Molecules, Peptides
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of AC01 in heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by AnaCardio. Primary endpoint: Absolute change from baseline in composite echocardiography Z-score at Week 12. Planned start Oct 2026; status: authorised.
02
Drugs
AC01
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2025-524469-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524469-25-00.